Behavioral and electroencephalographic studies of beagles with an Eck's fistula: suitability as a model of hepatic encephalopathy.
Behavioral manifestations, electroencephalograms (EEGs) and visually evoked potentials (VEPs) were studied in beagles with Eck's fistula (portacaval shunt [PCS]), an established model of hyperammonemia, to determine whether they developed CNS disorders characteristic of hepatic encephalopathy. After PCS, behavioral changes occurred in the form of listlessness, sluggishness (altered gait, snapping and transient catatonia-like symptoms) and apparent blindness, which appeared in that order and progressed to coma and death in some animals. The EEGs from the frontal cortex showed a gradual decrease in voltage and frequency. Development of snapping and catatonia-like symptoms coincided with the occurrence of high voltage fast waves in the EEGs from the occipital cortex. In comatose Eck's fistula dogs. flattening of the EEGs was recorded from the frontal cortex and a lowered voltage was noted in the EEGs from the occipital cortex. After PCS, the latencies and amplitudes of the components of VEP were increased. The snapping and catatonia-like symptoms were markedly ameliorated by carbamazepine and the coma by flumazenil and thyrotropin-releasing hormone. These findings indicate that Eck's fistula dogs provide a useful model of hepatic encephalopathy.
Watanabe
M
M
Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Japan.
Ozaki
T
T
Mushiroi
T
T
Ukai
Y
Y
Ueda
F
F
Kimura
K
K
Katoh
M
M
Matsumoto
A
A
Kotani
E
E
Itoh
S
S
Yamaguchi
K
K
Kyuki
K
K
D000641:Ammonia / Q000097:blood*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001522:Behavior, Animal / Q000502:physiology*; D002220:Carbamazepine / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004569:Electroencephalography; D005074:Evoked Potentials, Visual / Q000502:physiology*; D005442:Flumazenil / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D006501:Hepatic Encephalopathy / Q000503:physiopathology / Q000523:psychology*; D011167:Portacaval Shunt, Surgical; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D018756:GABA Antagonists; D002220:Carbamazepine; D005442:Flumazenil; D013973:Thyrotropin-Releasing Hormone; D000641:Ammonia